Keywords: Disease-modifying therapies, MS, Multiple sclerosis, Market forecasts, Decision Resources

Novel disease-modifying therapies will drive MS market to $11.5 billion in 2015

Article | 29 September 2011

The launch of several premium-priced novel disease-modifying therapies, including four oral agents, will drive the multiple sclerosis (MS) drug market ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in